ASX News

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)

Telix Pharmaceuticals is pleased to announce it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET).(1)

Telix’s NDA submission for TLX591-CDx includes clinical data from over 600 patients obtained from both prospective and retrospective clinical studies performed by Telix or in collaboration. The submission also builds on definitive peer-reviewed clinical research conducted at leading academic centres including the University of California, Los Angeles (USA), the Peter MacCallum Cancer Centre (Australia) and Heidelberg University Hospital (Germany).

Telix USA President Dr Bernard Lambert stated, “We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States. Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission. Subject to FDA approval, we look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer.”

Telix CEO Dr Christian Behrenbruch added, “Submitting an NDA to the US Food and Drug Administration for our first product is a major commercial inflection point for the Company and follows our European submission earlier this year. The Telix team and our advisors have done an outstanding job of preparing this submission, which we believe is founded on compelling clinical evidence that supports broad diagnostic utility in the management of prostate cancer. I’d like to acknowledge the commitment of our investigators, study teams and the independent physician readers who contributed to our clinical data package.”

Telix would like to gratefully acknowledge Eckert & Ziegler AG, IRE ELiT and GE Healthcare who collaborated closely with Telix to validate both 68Ge/68Ga generator and cyclotron-based 68Ga production systems with TLX591-CDx for the NDA submission. The Company wishes to particularly acknowledge and thank Memorial Sloan Kettering Cancer Center (MSKCC) and Advanced Accelerator Applications (a Novartis Company) for their significant contribution to the NDA submission and their commitment to men’s health.

(1)TLX591-CDx is not currently approved in any jurisdiction including the United States and European Union.

To read the full ASX release please click here.

More Articles

Corporate Spotlight

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

Melbourne (Australia) and Istanbul (Turkey) – 22nd October 2020. Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that...

Corporate Spotlight

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

12th October 2020 – Corporate Spotlight | Telix Pharmaceuticals will participate in AusBiotech + Invest 2020

Corporate Spotlight

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

12th October 2020 – Clinical Spotlight | Telix to Present at European Association of Nuclear Medicine 2020 Virtual Conference

ASX News

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Melbourne (Australia) – 6th October 2020. Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging...

ASX News

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...

ASX News

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...

ASX News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...

ASX News

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...

ASX News

FDA Grants Orphan Drug Designation for TLX102

Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...

ASX News

Half Year Shareholder Update

Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update

ASX News

First patient dosed in renal cancer imaging study in Japan

Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...

ASX News

Drug Master File for Glioblastoma Therapy Product Filed with FDA

Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...

ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...